英伟文校友现为美国Synta制药公司肿瘤药物研发高级总监。他带领团队研发了肺癌治疗药物Ganetespib，一种热休克蛋白90的抑制剂，现已处于临床III期试验阶段。Ganetespib作为非常有希望的新型抗癌药物，若其在临床试验中被证明有效，很有可能会给肺癌患者带来福音。

英伟文校友1989年毕业于中山大学化学系，同年免试保送上海有机所攻读硕士，在1992年硕士毕业后赴美，在克莱姆森大学获得博士学位，然后分别在耶鲁大学和纽约州立大学石溪分校进行有机合成和生物物理的博士后研究。他在2000年进入Synta公司并开始了研发之路。作为最新成果，这项药物在2007年进入了临床试验阶段，并且作为治疗非小细胞肺癌的特效药物接受了美国食品药品管理局的直通车式审查，现正处于最后审批阶段。

美国《C&EN》杂志对英伟文校友的成就给予了充分的肯定，“他们（英伟文校友和另两位中国化学家）的发明不仅延长了患者的生命，还为他们所在的生物科技公司带来了数以亿计的收益。”

       备注：《C&EN》杂志是美国化学学会（ACS）出版的新闻周刊，致力于关注化学化工界的最新事件。

 

C&EN封面

 

报道文章

附：英伟文校友简介

Dr. Weiwen Ying is Synta Fellow at Synta Pharmaceuticals (Nasdaq SNTA) in Lexington MA. He initiated and championed the discovery and development of ganetespib, an Hsp90 inhibitor, which is being evaluated in multiple clinical trials including a Phase III trial in lung cancer. As a prolific drug hunter, his experience in drug development ranges from conception of scientific ideas to managing relations with physicians and academic collaborators. Dr. Ying has published >20 peer-review journal articles and also has >30 issued or pending patents. Recently Weiwen and his colleague have developed the HDC (Hsp90-inhibitor Drug Conjugates) platform technology which has tremendous potential in creating an exciting, new class of anti-cancer therapies.

Prior to joining Synta in 2000, Dr. Ying was a postdoctoral fellow at SUNY Stony Brook and Yale University. He obtained Ph.D. in Organic Chemistry from Clemson University and M.S. from Shanghai Institute of Organic Chemistry, Chinese Academy of Science. He received his undergraduate degree from Sun Yat-sen University in Guangzhou, China.